SCENT
part 2. Identification of patients with lung cancer and breast cancer.

On the condition that such a discriminating algorithm can be deduced from the results of part 1, in part 2 of the SCENT study we will test the hypothesis that smellprints can identify and classify newly presented patients prospectively into the categories of non small cell lung cancer (NSCLC) and breast cancer.



Objective:

a. To determine the diagnostic accuracy of the electronic nose in establishing the sensitivity, specificity, positive and negative predictive value for detecting non small cell lung cancer in prospectively enrolled subjects (based on intention to diagnose in clinical practice);

b. To determine the diagnostic accuracy of the electronic nose in establishing the sensitivity, specificity, positive and negative predictive value for detecting breast cancer in prospectively enrolled subjects (based on intention to diagnose in clinical practice).




Study design:

diagnostic study.

This comprises prospective enrolment of new patients with an ‘intention to diagnose’ in order to determine the diagnostic accuracy of the electronic nose in the identification of NSCLC or breast cancer.



Study population:

All patients (18-80 yr) referred to the outpatient department pulmonary diseases for suspicion of lung cancer and at the outpatient department of surgery for suspicion of breast cancer.



Main study parameters/endpoints:

Sensitivity, specificity, positive and negative predictive value of the eNose in detecting NSCLC or breast cancer.

We will test the hypothesis that smellprints can identify and classify newly presented patients prospectively into the categories of non small cell lung cancer (NSCLC) and breast cancer.

Baseline measurement before histologic diagnosis is made.

N/A